Expression vectors comprising engineered genes
The invention provides expression vectors, nucleic acids, vector particles and methods of treatment involving these vector particles, comprising an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel, as well as methods of confirming the presence of engineered KCNA1 mRNA in a cell. The features of the engineered KCNA1 gene combine to advantageously enhance the translation and activity of the Kv1.1 protein and improve detection of KCNA1 gene expression in a cell and can be used for example in the treatment of epilepsy and similar neurological disorders.
1. An expression vector comprising an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel operably linked to a promoter suitable to drive expression of the edited Kv1.1 potassium channel in human cells,
wherein the engineered KCNA1 gene has a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO: 1.
2. The expression vector of claim 1 , wherein the promoter is a cell type specific promoter, which is optionally a promoter specific for neurons.
3. The expression vector of claim 2 , wherein the cell type specific promoter is specific for pyramidal neurons.
4. The expression vector of claim 2 , wherein the cell type specific promoter comprises a human CAMK2A promoter.
5. The expression vector of claim 4 , wherein the human CAMK2A promoter has a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO: 3.
6. The expression vector of claim 1 , wherein the vector is a viral vector.
7. The expression vector of claim 6 , wherein the viral vector is a lentiviral vector, optionally wherein the lentiviral vector is a non-integrating lentiviral vector.
8. An in vitro method of making viral particles comprising transducing mammalian cells with the lentiviral vector according to claim 7 and expressing viral packaging and envelope proteins necessary for particle formation in the cells; and
culturing the transduced cells in a culture medium, such that the cells produce lentiviral particles that are released into the medium.
9. The in vitro method of claim 8 , wherein the method comprises transducing the mammalian cells with one or more viral packaging and envelope expression vectors that encode the viral packaging and envelope proteins necessary for particle formation.
10. The in vitro method of claim 8 , wherein the packaging proteins include a non-functional integrase enzyme such that the lentiviral vector is unable to incorporate its viral genome into the genome of the cells.
11. The in vitro method of claim 8 , further comprising separating the viral particles from the culture medium and optionally concentrating the viral particles.
12. A viral particle derived from the lentiviral vector of claim 7 .
13. A method of treatment of a neurological disorder associated with neuronal hyperexcitability comprising administering to an individual with the neurological disorder the viral particle of claim 12 .
14. The method of treatment of claim 13 , wherein the neurological disorder is a seizure disorder.
15. The method of treatment according to claim 14 , wherein the seizure disorder is epilepsy, which is optionally neocortical epilepsy.
16. The method of treatment of claim 13 , wherein the neurological disorder is Parkinson's disease or chronic pain.
17. An in vitro or ex vivo method of confirming the presence of engineered KCNA1 mRNA in a cell that has been obtained from a subject administered the viral particle of claim 12 , the method comprising:
detecting the presence of engineered KCNA1 mRNA in the cell using a hybridisation assay.
18. A kit comprising the expression vector of claim 7 and a viral packaging and envelope expression vector that encodes viral packaging and envelope proteins necessary for particle formation when expressed in a cell, wherein the viral packaging expression vector is optionally an integrase-deficient viral packaging expression vector.
19. A method of confirming the presence of engineered KCNA1 mRNA in a cell, the method comprising:
transducing a cell with the expression vector of claim 1 under conditions that permit expression of engineered KCNA1 mRNA; and
detecting the presence of the engineered KCNA1 mRNA in the cell using a hybridisation assay.
20. A cell comprising the expression vector of claim 1 , wherein the cell is optionally a mammalian cell, which is optionally a human cell, which is optionally a human embryonic kidney cell.
21. An expression vector, which is a lentiviral vector, comprising an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel operably linked to a promoter suitable to drive expression of the edited Kv1.1 potassium channel in human cells, wherein the edited Kv1.1 potassium channel has an amino acid sequence comprising or consisting of the amino acid sequence of SEQ ID NO: 2, and wherein the lentiviral vector comprises a nucleotide sequence having at least 95% identity to the nucleotide sequence of SEQ ID NO: 9.
22. The expression vector of claim 21 , wherein the promoter is a cell type specific promoter, wherein the promoter is specific for neurons.
23. The expression vector of claim 22 , wherein the cell type specific promoter is specific for pyramidal neurons.
24. The expression vector of claim 22 , wherein the cell type specific promoter comprises a human CAMK2A promoter, wherein the human CAMK2A promoter has a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO: 3.
25. A nucleic acid comprising an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel, wherein the engineered KCNA1 gene has a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO: 1.